Australis Appoints Dr. Jason Dyck as Chief Science Officer
Australis Capital Inc. (CSE: AUSA, OTC: AUSAF) has appointed Dr. Jason Dyck as Chief Science Officer and Chairman of its Scientific Advisory Board. This strategic move aims to strengthen the company's focus on medical and wellness applications of cannabis. Dr. Dyck brings extensive experience from his tenure at Aurora Cannabis and has created the largest medical cannabis patient database in the world. He will guide scientific efforts and explore partnerships to enhance AUSA's innovation in the cannabis sector.
- Dr. Dyck's appointment aligns with AUSA's strategy to enhance offerings in medical cannabis.
- Dr. Dyck possesses significant industry experience, having previously led research at Aurora Cannabis.
- The world’s largest medical cannabis database under Dr. Dyck's oversight may enhance research and product development.
- The Scientific Advisory Board's goal includes identifying valuable partnerships, potentially increasing revenue streams.
- Concerns may arise regarding the continuity of AUSA's existing scientific initiatives with new leadership.
- Dr. Dyck's ability to seamlessly integrate and lead in a new corporate culture could pose challenges.
LAS VEGAS, April 12, 2021 /PRNewswire/ - Australis Capital Inc. (CSE: AUSA) (OTC: AUSAF) ("AUSA" or the "Company") today announced it has appointed Dr. Jason Dyck as its new Chief Science Officer, and Chairman of its Scientific Advisory Board. (SAB).
The appointment is in line with the Company's strategy to leverage the roots of its management team in medical cannabis, and develop offerings and partnerships that are aimed at the medical and wellness markets. Dr. Dyck has a wealth of experience in leading cannabis related medical research, as well as has deep connections and a high standing throughout the industry. Previously, Dr. Dyck led the research and science team at Aurora Cannabis in its formative years, playing a significant role in helping it become the medical cannabis industry leader that it is today.
In addition, a component of Dr. Dyck's research at the University of Alberta involves the study of medical cannabis users. Dr. Dyck has established the world's largest known medical cannabis database of over 160,000 patients that links these patients to comprehensive provincial administrative health data. This type of database is being used by Dr. Dyck and his colleagues at the University of Alberta to determine how medical cannabis use influences use of other medications, health insurance claims, acute and ambulatory care episodes, accident claims, and other key health outcomes.
In this newly created position, Dr. Dyck will be responsible for leading the Company's scientific efforts in relation to medical and wellness applications for cannabis, both THC and CBD, as well as play an important role in the identification and vetting of partnership opportunities with medical and science-based innovators. The SAB mandate will include, but is not limited to, providing advice, analysis and direction related to the scientific investigation, development and market implementation of possible human use and/or consumption of products derived from Cannabis and/or Hemp containing cannabinoids and terpenes.
Management Commentary
Dr. Dyck commented, "I am very excited about taking on this new responsibility at AUSA. We believe that medical science will play an increasingly important role in the development of the cannabis industry. I look forward to providing AUSA with advice and direction in its scientific efforts towards bringing innovations to market with immediate and significant commercial appeal."
Dr. Duke Fu, COO at AUSA, added, "We believe that Jason's capabilities and connections in medical science and the cannabis industry will prove tremendous assets for the Company as we look to develop commercially valuable innovations for the medical, wellness and adult use markets. I look forward to working with Jason as we take AUSA's scientific efforts to the next level."
Dr. Dyck
Dr. Dyck serves in many leadership roles, including as the director of the Cardiovascular Research Centre at the University of Alberta, Canada. Dr. Dyck also established and co-directs a province-wide clinical heart failure research program called Alberta HEART that is a translational research program in heart failure. This leadership fosters collaborations, and promotes translational research at the local, provincial, and national levels.
The quality, quantity and impact of Dr. Dyck's research has been substantial. He has published over 230 peer-reviewed papers in high quality journals. An impressive feature of his program is that Dr. Dyck advances his basic research findings to clinical research by obtaining peer-reviewed funding for clinical trials, which has contributed to his translational research productivity. Dr. Dyck has received many research distinctions, including being named a fellow of the Canadian Academy of Health Sciences, the Canadian Hypertension Society/Pfizer Award, the Averback Gene Therapy Award, the Hypertension Top Paper Award and he was recognized as one of Canada's Top 40 Under 40 (2007). Moreover, Dr. Dyck has received many salary awards (12), and he is currently a Canada Research Chair in Molecular Medicine.
Dr. Dyck received a PhD in Medical Sciences from the University of Alberta in 1995 and trained at Dartmouth Medical School (Hanover, New Hampshire) and Baylor College of Medicine (Houston, Texas).
About Australis Capital Inc.
AUSA is implementing a capital light growth strategy towards establishing a highly competitive and profitable MSO in the U.S. and global cannabis markets. AUSA's business lines and assets include a
The Company's common shares trade on the CSE under the symbol "AUSA" and on the OTCQB under the symbol "AUSAF".
"Terry Booth"
________________________________
Terry Booth
Chief Executive Officer
Forward-Looking Statement
This press release contains "forward-looking information" within the meaning of applicable securities legislation. All statements, other than statements of historical fact, included herein is forward-looking information. Generally, forward-looking information may be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "proposed", "is expected", "budgets", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. In particular, this press release contains forward-looking information in relation to: the timing and ability to close the proposed transaction; the anticipated development of the GT business and its ability to grow revenues; the proposed transaction being immediately accretive to the Company's financial position; the ability of the Company to scale up the GT assets across multiple jurisdictions; the ability for the Company to be able to execute on its plans for expansion in Oklahoma, Missouri and other markets; the impact of the changes to U.S. federal and state developments with respect to the cannabis industry and the opportunities this may present for the Company; and the Company's current liquidity. This forward-looking information reflects the Company's current beliefs and is based on information currently available to the Company and on assumptions the Company believes are reasonable. These assumptions include, but are not limited to: the ability of the Company to successfully satisfy the conditions to closing the proposed transaction; the ability of the Company to successfully execute on its plans for the Company and GT; legal changes relating to the cannabis industry proceeding as anticipated; and the Company's continued response and ability to navigate the COVID-19 pandemic being consistent with, or better than, its ability and response to date.
Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; the actual results of the Company's future operations; competition; changes in legislation affecting the Company; the timing and availability of external financing on acceptable terms; lack of qualified, skilled labour or loss of key individuals; risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures, service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, economic activity, financing, supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession; and a deterioration of financial markets that could limit the Company's ability to obtain external financing.
A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in the Company's disclosure documents on the SEDAR website at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Accordingly, readers should not place undue reliance on forward-looking information. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
Forward-looking information contained in this press release is expressly qualified by this cautionary statement. The forward-looking information contained in this press release represents the expectations of the Company as of the date of this press release and, accordingly, are subject to change after such date. However, the Company expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
The CSE has neither approved nor disapproved the contents of this news release. Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accept responsibility for the adequacy or accuracy of this release.
View original content to download multimedia:http://www.prnewswire.com/news-releases/australis-appoints-dr-jason-dyck-as-chief-science-officer-301266605.html
SOURCE Australis Capital Inc.
FAQ
Who is Dr. Jason Dyck and what experience does he bring to Australis Capital Inc.?
What is the role of Dr. Dyck at Australis Capital Inc.?
How might Dr. Dyck's appointment impact AUSA's future?
What are the strategic goals of Australis Capital Inc. following Dr. Dyck's appointment?
